Publicaciones en colaboración con investigadores/as de Hospital Virgen de la Arrixaca (19)

2024

  1. Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta-analysis

    Liver International, Vol. 44, Núm. 1, pp. 250-262

2022

  1. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation

    American Journal of Transplantation, Vol. 22, Núm. 6, pp. 1671-1682

2019

  1. Extracellular adenosine reversibly inhibits the activation of human regulatory T cells and negatively influences the achievement of the operational tolerance in liver transplantation

    American Journal of Transplantation, Vol. 19, Núm. 1, pp. 48-61

  2. Tolerance biomarkers in liver transplantation: Independent external validation of the predictive strength of SENP6 and FEM1c gene expression

    Transplantation, Vol. 103, Núm. 9, pp. 1887-1892

2017

  1. Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil

    Liver Transplantation, Vol. 23, Núm. 4, pp. 498-509

  2. Differential profile of activated regulatory T cell subsets and microRNAs in tolerant liver transplant recipients

    Liver Transplantation, Vol. 23, Núm. 7, pp. 933-945

  3. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study

    Transplant International, Vol. 30, Núm. 10, pp. 1041-1050

  4. Real-world multicenter experience of immunosuppression minimization among 661 liver transplant recipients

    Annals of Transplantation, Vol. 22, pp. 265-275

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2015

  1. Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin

    Transplant Infectious Disease, Vol. 17, Núm. 2, pp. 208-220

  2. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain

    Liver Transplantation, Vol. 21, Núm. 8, pp. 1056-1065

  3. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante

    Cirugia Espanola, Vol. 93, Núm. 10, pp. 619-637

2014

  1. "very early" intrahepatic cholangiocarcinoma in cirrhotic patients: Should liver transplantation be reconsidered in these patients?

    American Journal of Transplantation, Vol. 14, Núm. 3, pp. 660-667

  2. IV Reunión de Consenso de la Sociedad Española de Trasplante Hepático 2012. Excepciones al Model for End-stage Liver Disease en la priorización para trasplante hepático

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 2, pp. 83-91

  3. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: A spanish matched cohort multicenter study

    Annals of Surgery, Vol. 259, Núm. 5, pp. 944-952

2005

  1. An open, randomized, multicenter clinical trial of oral tacrolimus in liver allograft transplantation: A comparison of dual vs. triple drug therapy

    Liver Transplantation, Vol. 11, Núm. 5, pp. 515-524

2003

  1. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation

    Journal of Hepatology

2002

  1. Tacrolimus is effective in both dual and triple regimens after liver transplantation

    Transplantation Proceedings

1998

  1. Liver transplantation in hepatitis C. A Spanish multi-centre experience

    European Journal of Gastroenterology and Hepatology, Vol. 10, Núm. 9, pp. 771-776